Industry challenge / “scare” points
FDA approval often creates a false sense of readiness when MedTech companies plan their European market entry. Many non-EU manufacturers underestimate the regulatory and clinical differences in Europe, leading to Notified Body delays, unexpected evidence gaps, and unpredictable timelines and costs under MDR and IVDR.
What the webinar will cover
This webinar builds on QbD Group’s Landing in Europe MedTech whitepaper and explains why EU market entry requires a fundamentally different approach. The session will explore where home-market regulatory logic breaks down in Europe, with a specific focus on clinical evidence expectations, Notified Body interactions, and lifecycle obligations.
What attendees will learn
Using real-world experience, the webinar will outline the EU market entry lifecycle, from early EU readiness and gap assessment to CE marking and post-market compliance. Particular attention will be given to why regulatory and clinical planning must be integrated from day one to reduce risk and regain control over timelines and costs.
Call to action
Attendees will leave with a clearer view of their true EU readiness and the steps required to achieve predictable and sustainable European market success. Register to assess your own risks, avoid costly delays, and understand what it really takes to enter Europe successfully.
Key Learning Objectives
- Understand why FDA or NMPA approval does not automatically translate into EU readiness.
- Identify where regulatory and clinical expectations differ in Europe and how this impacts timelines and risk.
- Learn how an integrated regulatory and clinical strategy enables more predictable EU market entry.
